• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Harpoon Therapeutics

    Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma
    From Harpoon Therapeutics
    Via GlobeNewswire
    Tickers HARP
    Harpoon Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
    From Harpoon Therapeutics
    Via GlobeNewswire
    Tickers HARP
    Harpoon Therapeutics Presents Preclinical Results for Novel T Cell Engagers HPN217 and HPN328 at AACR 2023
    From Harpoon Therapeutics
    Via GlobeNewswire
    Tickers HARP
    Harpoon Therapeutics Presents Data for New ProTriTAC™ Development Candidates in TROP2- and ITGB6-expressing Solid Tumors at AACR 2023
    From Harpoon Therapeutics
    Via GlobeNewswire
    Tickers HARP
    Harpoon Therapeutics to Participate in the Canaccord Horizons in Oncology Conference
    From Harpoon Therapeutics
    Via GlobeNewswire
    Tickers HARP
    Harpoon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
    From Harpoon Therapeutics
    Via GlobeNewswire
    Tickers HARP
    Harpoon Therapeutics Announces Closing of $25 Million Private Placement
    From Harpoon Therapeutics
    Via GlobeNewswire
    Tickers HARP
    Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023
    From Harpoon Therapeutics
    Via GlobeNewswire
    Tickers HARP
    Harpoon Therapeutics to Participate in the SVB Securities Global Biopharma Conference
    From Harpoon Therapeutics
    Via GlobeNewswire
    Tickers HARP
    Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma
    From Harpoon Therapeutics
    Via GlobeNewswire
    Tickers HARP
    Harpoon Therapeutics to Host HPN217 Interim Results and Corporate Update Call and Webcast on December 12, 2022
    From Harpoon Therapeutics
    Via GlobeNewswire
    Tickers HARP
    Harpoon Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference
    From Harpoon Therapeutics
    Via GlobeNewswire
    Tickers HARP
    Harpoon Therapeutics Updates Strategic Priorities and Reports Third Quarter 2022 Financial Results
    From Harpoon Therapeutics
    Via GlobeNewswire
    Tickers HARP
    Harpoon Therapeutics to Present Interim Results from Phase 1 Clinical Trial of T Cell Engager HPN217 at the 64th ASH Annual Meeting and Exposition
    From Harpoon Therapeutics
    Via GlobeNewswire
    Tickers HARP
    Harpoon Therapeutics Appoints Luke Walker, M.D., as Chief Medical Officer
    From Harpoon Therapeutics
    Via GlobeNewswire
    Tickers HARP
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.